BRIAN EKBERG: Open Payments
NPI 1992759583 · BOUNTIFUL, UT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,207 in 74 payments from 20 companies in 2025. Trend: 2023 $0 · 2024 $715 · 2025 $1,207
Food & beverage: $1,207
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 18 | $239 |
| Lilly USA, LLC | 12 | $161 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $109 |
| Amgen Inc. | 6 | $94 |
| Janssen Pharmaceuticals, Inc | 3 | $74 |
| Astellas Pharma US Inc | 4 | $71 |
| GlaxoSmithKline, LLC. | 4 | $69 |
| Otsuka America Pharmaceutical, Inc. | 4 | $65 |
| AstraZeneca Pharmaceuticals LP | 4 | $60 |
| Abbott Laboratories | 2 | $44 |
Products named: CAPLYTA, MOUNJARO, VRAYLAR, REXULTI, QULIPTA, SPRAVATO, UBRELVY, Veozah.
Industry payments across UT — which companies pay providers there.
